Company news
NovoCure Limited news in 2022
NovoCure Limited's news releases, calls and decks from 2022, newest first.
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
December 26, 2022
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
November 28, 2022
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
November 22, 2022
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
November 16, 2022
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
November 14, 2022
Novocure Secures CE Mark for New Array
November 10, 2022
Novocure Reports Third Quarter 2022 Financial Results
October 26, 2022
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
October 20, 2022
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
October 19, 2022
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
October 19, 2022
Novocure to Report Third Quarter 2022 Financial Results
October 2, 2022
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
September 20, 2022
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
August 9, 2022
Novocure Reports Second Quarter 2022 Financial Results
July 27, 2022
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
July 26, 2022
Novocure to Report Second Quarter 2022 Financial Results
June 30, 2022
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
June 20, 2022
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
June 2, 2022
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
May 25, 2022
Novocure Reports First Quarter 2022 Financial Results
April 27, 2022
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
April 18, 2022
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
April 7, 2022
Novocure to Report First Quarter 2022 Financial Results
March 31, 2022
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
March 23, 2022
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
March 22, 2022
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
February 27, 2022
Novocure’s General Counsel Resigns After 10 Years of Service
February 23, 2022
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
February 23, 2022
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
February 23, 2022
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
January 9, 2022
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Calls in 2022
Decks in 2022
- Investor Presentation (July 2022)
Investor deck · 45 slides · July 2022